A single infusion of ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma resulted in an overall response rate of 95%. Read More ›

In the phase 3 DETERMINATION trial—in which patients with newly diagnosed multiple myeloma were randomly assigned to a standard triplet regimen with and without autologous stem-cell transplantation (ASCT), with all receiving lenalidomide (Revlimid) maintenance therapy until disease progression—patients with ASCT had significantly longer progression-free survival (PFS) versus those who did not, but no difference in overall survival (OS) was observed between the 2 treatment arms. Read More ›

Minimal residual disease assessments are increasingly being used in the clinical trial setting. Read More ›

Updated analysis of IKEMA showed improved responses with isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma. Read More ›

Ciltacabtagene autoleucel has been shown to have compelling survival benefit, and a new study shows improved health-related quality of life in patients with triple-class exposed multiple myeloma. Read More ›

Final analysis of ICARIA-MM supports isatuximab plus pomalidomide and dexamethasone as standard of care in patients with relapsed/refractory multiple myeloma. Read More ›

Continuing medical education and nursing continuing professional development–approved activities can improve clinicians’ knowledge of the fast-emerging treatment landscape in multiple myeloma. Read More ›

Daratumumab plus lenalidomide and dexamethasone showed deep clinical responses in patients who continued treatment for ≥18 months. Read More ›

Final results from the LYRA study demonstrate daratumumab plus cyclophosphamide, bortezomib, dexamethasone was well-tolerated and effective in patients with newly diagnosed or relapsed/refractory multiple myeloma. Read More ›

Patient and caregiver preferences are important factors in selecting treatments. Read More ›